
KIORA PHARMACEUTICALS INC
94
Recent developments include Kiora’s reporting of third quarter 2026 financial results and in-licensing of KIO-401, entering an exclusive license agreement with Senju Pharmaceutical for KIO-401, closing a private placement for up to $24 million, and ongoing clinical trial progress with data readouts anticipated in 2027.
- Kiora Pharmaceuticals reported third quarter 2026 financial results and announced the in-licensing of KIO-401 [N1].
- The company entered an exclusive license agreement with Senju Pharmaceutical Co., Ltd. for KIO-401, receiving $1.25 million upfront and potential milestone payments and royalties [N2].
- Kiora closed a private placement raising up to $24 million in April 2026 [N3].
- Data readouts for the ABACUS-2 and KLARITY clinical trials are anticipated in 2027 [N4].
- Kiora’s Q2 2025 revenue fell 100%, reflecting the early-stage nature of its business [N5].
- The company reported quarterly earnings results in March 2025 [N6].
- Kiora gained approval for a Phase 2 trial in October 2024 [N7].
- Analysis articles have discussed valuation and study updates for Kiora Pharmaceuticals [N8].
Kiora Pharmaceuticals Inc focuses on developing and commercializing therapies for retinal diseases. Its lead product candidate, KIO-301, is a novel photoswitch small molecule designed to restore vision in patients with inherited and age-related retinal degenerative diseases such as retinitis pigmentosa. KIO-301 has completed Phase 1b trials demonstrating safety and vision improvements and is currently in a Phase 2 trial (ABACUS-2) enrolling patients with advanced vision loss. The company also develops KIO-104, a DHODH inhibitor targeting retinal inflammatory diseases including diabetic macular edema and posterior non-infectious uveitis, with ongoing Phase 2 trials (KLARITY). KIO-101, a topical formulation of the same active compound as KIO-104, targets ocular manifestations of autoimmune diseases and is being considered for strategic partnerships. Kiora has collaborations with Théa Open Innovation for global development and commercialization of KIO-301 and an exclusive license agreement with Senju Pharmaceutical for KIO-401 in Asia. The company’s strategy includes advancing clinical development, seeking partnerships, and expanding indications and intellectual property.
Kiora Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company developing therapies for retinal diseases, including retinitis pigmentosa and retinal inflammation. The company is advancing clinical trials for its lead assets KIO-301 and KIO-104, with ongoing Phase 2 studies and recent positive Phase 1b results. Kiora has entered strategic partnerships, including a license agreement with Senju Pharmaceutical for KIO-401 and a collaboration with Théa Open Innovation for KIO-301. Financially, as of September 30, 2026, the company reported $19.91 million in current assets, a strong liquidity position with a current ratio of 7.91, $1 million in quarterly revenue, and a net loss of $1.75 million. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Kiora Pharmaceuticals has advanced clinical-stage assets addressing retinal diseases with no approved therapies, including KIO-301 for retinitis pigmentosa and KIO-104 for retinal inflammation. Positive Phase 1b data and ongoing Phase 2 trials support continued development. Strategic partnerships with Théa Open Innovation and Senju Pharmaceutical provide funding, development support, and potential milestone payments. Orphan drug designations in the US and Europe offer regulatory advantages and market exclusivity potential. The company’s strong liquidity position as of Q3 2026 supports ongoing operations and clinical programs. Collaborations and acquisitions have expanded the pipeline and intellectual property portfolio, positioning Kiora to address multiple ophthalmic indications.
Kiora Pharmaceuticals faces risks including the need to meet significant milestone payments and development obligations under its license agreement with Senju Pharmaceutical for KIO-401, with potential termination if unmet. Clinical data generated by Senju in Japan may not be accepted by US or other regulators, possibly requiring additional costly trials. The company is in early clinical stages with no approved products and has reported net losses. The success of clinical trials is uncertain, and failure to demonstrate safety or efficacy could impair development. The company’s financial resources, while currently sufficient, may be strained by development costs and milestone payments. Market competition and regulatory challenges in ophthalmology add to execution risks.
Kiora Pharmaceuticals’ moat is based on its proprietary small molecule therapies with novel mechanisms of action targeting retinal diseases with high unmet medical need and no approved treatments, such as retinitis pigmentosa and retinal inflammation. The company has secured orphan drug designations in the US and Europe, providing regulatory incentives and potential market exclusivity. Strategic partnerships with established pharmaceutical companies like Théa Open Innovation and Senju Pharmaceutical provide development and commercialization resources and milestone funding. Its clinical-stage assets have demonstrated safety and early efficacy signals, supported by intellectual property portfolios. The specialized focus on ophthalmic diseases and novel photoswitch and DHODH inhibitor platforms contribute to differentiation in a niche market with significant barriers to entry.
• License and Milestone Payment Obligations: Kiora must make significant milestone payments and meet development obligations under its license agreement with Senju Pharmaceutical for KIO-401. Failure to meet these obligations could result in termination of rights and loss of intellectual property, materially harming the business.
• Regulatory Acceptance of Clinical Data: Clinical data generated by Senju in Japan may not be accepted by the FDA or other regulators, potentially requiring additional clinical trials that increase development costs and delay commercialization.
• Clinical Development Risks: Kiora’s product candidates are in early clinical stages with inherent risks of failure to demonstrate safety or efficacy, which could adversely affect the company’s prospects.
• Financial Risks: The company has reported net losses and depends on capital raises and milestone payments to fund operations. Insufficient funding could impair development programs and business operations.
Business trends: Advancement of clinical-stage retinal disease therapies with ongoing Phase 2 trials and strategic partnerships expanding development and commercialization.
Execution milestones: Data readouts from ABACUS-2 and KLARITY trials anticipated in 2027; continued enrollment and regulatory progress; milestone payments and license obligations management.
Key risks: Potential failure to meet license obligations under Senju agreement, regulatory acceptance of clinical data, clinical trial risks, and financial resource constraints.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Kiora Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company focused on developing therapies for retinal diseases, including retinitis pigmentosa (RP), diabetic macular edema (DME), posterior non-infectious uveitis, and ocular manifestations of autoimmune diseases [S1].
- The company is developing KIO-301, a novel small molecule photoswitch designed to restore vision in patients with inherited and age-related degenerative retinal diseases such as RP. KIO-301 completed a Phase 1b clinical trial in September 2023 with topline results announced in November 2023 showing safety and vision improvements [S1].
- KIO-301 is in an ongoing Phase 2 clinical trial (ABACUS-2) enrolling patients with ultra-low vision or no light perception due to RP. The trial is a 36-patient, multicenter, double-masked, randomized, controlled, multiple dose study [S1].
- KIO-301 has received Orphan Drug Designation (ODD) from the FDA and Orphan Medicinal Product Designation from the European Medicines Agency for treatment of rod-dominant retinal dystrophies including RP and Usher syndrome [S1].
- KIO-104 is a small-molecule DHODH inhibitor in development for retinal inflammatory diseases such as DME and posterior non-infectious uveitis. It has shown safety and promising efficacy signals in a Phase 1b/2a study, including improvements in visual acuity and inflammation [S1].
- The KLARITY Phase 2 trial for KIO-104 in retinal inflammation began enrollment in Q2 2025 and dosing started in Q3 2025 [S1].
- KIO-101 is a topical ophthalmic formulation of the same active compound as KIO-104, targeting ocular manifestations of autoimmune diseases like rheumatoid arthritis (OPRA+). The company is seeking strategic partnerships for KIO-101 [S1].
- Kiora entered an exclusive license agreement with Senju Pharmaceutical Co., Ltd. for KIO-401, granting Senju rights in certain Asian countries. Kiora received $1.25 million upfront and may receive up to $109.5 million in milestones plus royalties. KIO-401 is subject to development and payment obligations [S1][N2].
- Kiora has a collaboration with Théa Open Innovation (TOI) for global rights (excluding certain Asian countries) to co-develop and commercialize KIO-301. Kiora received $16 million upfront and may receive up to $285 million in milestones plus royalties. TOI funds all R&D costs for KIO-301 [S1].
- The company closed a private placement raising up to $24 million in April 2026 [N3].
- Financial snapshot as of September 30, 2026: cash and equivalents $5.57 million, short-term investments $10.72 million, current assets $19.91 million, current liabilities $2.52 million, current ratio 7.91, cash ratio 6.47. Revenue for the quarter was $1 million with a net loss of $1.75 million and basic/diluted EPS of -$0.28 [S2].
- Kiora's strategy focuses on advancing clinical development of core assets KIO-301 and KIO-104, seeking partnerships for KIO-101, and pursuing collaborations to expand indications and intellectual property [S1].
- The company has ongoing clinical trials with data readouts anticipated in 2027 for ABACUS-2 and KLARITY [N4].
- Kiora's pipeline includes assets acquired through acquisitions: KIO-301 from Bayon Therapeutics and KIO-104 from Panoptes Pharma GmbH [S1].
- The company faces risks related to milestone payments and development obligations under the Senju license for KIO-401, including potential termination if obligations are unmet, which would materially harm the business [S1].
- Clinical data generated by Senju in Japan may not be accepted by FDA or other regulators, possibly requiring additional trials and increasing development costs [S1].
Generated 2026-11-15
- S1 | 2026-03-25 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-13 | www.nasdaq.com | Kiora Pharmaceuticals Reports Third Quarter 2026 Financial Results and KIO-401 In-Licensing | https://www.nasdaq.com/articles/kiora-pharmaceuticals-reports-third-quarter-2026-financial-results-and-kio-401-licensing
- N2 | 2026-10-29 | www.nasdaq.com | Kiora Pharmaceuticals, Inc. Enters Exclusive License Agreement with Senju Pharmaceutical Co., Ltd. for KIO-401 | https://www.nasdaq.com/articles/kiora-pharmaceuticals-inc-enters-exclusive-license-agreement-senju-pharmaceutical-co-ltd
- N3 | 2026-04-07 | www.nasdaq.com | Kiora Pharma Closes Private Placement For Up To $24 Mln; Stock Up | https://www.nasdaq.com/articles/kiora-pharma-closes-private-placement-24-mln-stock
- N4 | 2025-11-04 | www.nasdaq.com | Eyes On Kiora - ABACUS-2 And KLARITY Data Readouts Due In 2027 | https://www.nasdaq.com/articles/eyes-kiora-abacus-2-and-klarity-data-readouts-due-2027
- N5 | 2025-08-08 | www.nasdaq.com | Kiora (KPRX) Q2 Revenue Falls 100% | https://www.nasdaq.com/articles/kiora-kprx-q2-revenue-falls-100
- N6 | 2025-03-25 | www.nasdaq.com | KIORA PHARMACEUTICALS Earnings Results: $KPRX Reports Quarterly Earnings | https://www.nasdaq.com/articles/kiora-pharmaceuticals-earnings-results-kprx-reports-quarterly-earnings
- N7 | 2024-10-29 | www.nasdaq.com | Kiora Pharmaceuticals Gains Approval for Phase 2 Trial | https://www.nasdaq.com/articles/kiora-pharmaceuticals-gains-approval-phase-2-trial
- N8 | 2024-06-18 | www.nasdaq.com | Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now? | https://www.nasdaq.com/articles/kiora-pharmaceuticals-kprx-stock-undervalued-right-now
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


